Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Activating mutations in the epidermal growth factor receptor (EGFR) kinase domain are common in non-small cell lung cancer (NSCLC).
• While ATP mimetics targeting EGFR tyrosine kinase are effective, the role of antibodies targeting the EGFR ectodomain remains less understood.

Purpose of the Study:

• To investigate the effects and mechanisms of the antibody cetuximab on lung cancer cells with EGFR mutations.
• To evaluate cetuximab's efficacy in both naturally occurring and engineered EGFR mutant models.

Main Methods:

• Treatment of lung cancer cells and ErbB-null 32D cells transfected with mutant EGFR with cetuximab.
• Assessment of EGFR levels, cell growth in vitro and in vivo, and EGFR signaling pathways.
• Investigation of the role of receptor dimerization using monovalent Fab fragments.

Main Results:

• Cetuximab treatment down-regulated EGFR levels and inhibited cell growth, independent of ligand action.
• Antibody-induced EGFR down-regulation and growth inhibition required receptor dimerization.
• Cetuximab demonstrated efficacy against H1975 lung cancer cells and xenografts with L858R/T790M EGFR mutations, which are resistant to tyrosine kinase inhibitors.

Conclusions:

• Cetuximab is an effective therapeutic agent against cancer cells expressing mutant EGFR.
• Cetuximab shows potential as a combination therapy with other anti-EGFR molecules, particularly for resistant NSCLC cases.